Company profile
KARYOPHARM THERAPEUTICS INC.
NASDAQ:KPTIBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| XPOVIO | approved | $30.8MQ2 2026 | 32 | approved |
| ELTANEXOR | phase1_2 | — | 1 | no active trials |
| PADNARSERTIB | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01896505 | phase1 | completed | 2013-07-30 | 2016-10-21 | Karyopharm Therapeutics Inc | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma |
| NCT04442022 | phase2_3 | active_not_recruiting | 2020-09-03 | 2026-12-01 | Karyopharm Therapeutics Inc | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT04414475 | phase2 | recruiting | 2020-07-01 | 2028-01-01 | Karyopharm Therapeutics Inc | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. |
| NCT05980806 | phase2 | recruiting | 2024-04-22 | 2027-06-01 | Karyopharm Therapeutics Inc | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
| NCT04421378 | phase1_2 | terminated | 2020-06-08 | 2023-07-03 | Karyopharm Therapeutics Inc | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212306 | 2019-07-03 | NDA | KARYOPHARM THERAPEUTICS INC | |||||
Loading… | ||||||||